#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	18810	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2512	923.1	0	.	n	.	0	G1207A	SNP	1207	1207	G	1690	1690	A	1197	A,C	1196,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	18810	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2512	923.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1933	1933	T	1222	T,G	1217,5	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	18810	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2512	923.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1667	1667	C	1202	C	1202	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30876	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4146	928.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1978	1978	A	1296	A,G,C	1294,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30876	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4146	928.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2612	2612	C	1045	C,T	1044,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30876	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4146	928.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2686	2686	A	985	A,T,G	983,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30876	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4146	928.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3238	3238	C	1139	C,T,A	1136,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2732	folP	852	852	99.77	folP.l6.c4.ctg.1	2037	166.9	0	.	p	.	0	D71H	NONSYN	211	213	GAT	811	813	CAT	231;233;238	C;A;T,C	231;233;237,1	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2732	folP	852	852	99.77	folP.l6.c4.ctg.1	2037	166.9	0	.	p	.	0	A204V	NONSYN	610	612	GCA	1210	1212	GTA	250;251;255	G;T;A,C	250;251;254,1	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2732	folP	852	852	99.77	folP.l6.c4.ctg.1	2037	166.9	1	SNP	p	R228S	0	.	.	682	684	CGC	1282	1284	CGC	267;267;265	C;G;C	267;267;265	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6584	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3793	216.3	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1244	1246	ATA	265;263;262	A;T;A,C	265;263;261,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6584	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3793	216.3	1	SNP	p	S91F	0	.	.	271	273	TCC	767	769	TCC	245;247;248	T;C;C	245;247;248	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6584	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3793	216.3	1	SNP	p	D95G	0	.	.	283	285	GAC	779	781	GAC	264;267;268	G;A,G;C	264;266,1;268	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6584	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3793	216.3	1	SNP	p	D95N	0	.	.	283	285	GAC	779	781	GAC	264;267;268	G;A,G;C	264;266,1;268	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2410	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1719	174.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1374	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1484	115.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1739	1741	GTC	307;307;308	G,T;T,C;C	305,2;306,1;308	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1892	1894	GCA	304;305;310	G;C,A;A,C	304;304,1;309,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2375	2377	ATT	306;308;305	A,C;T,G;T	305,1;306,2;305	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	1	SNP	p	D86N	0	.	.	256	258	GAC	845	847	GAC	270;266;264	G;A,G;C	270;265,1;264	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	1	SNP	p	S87R	0	.	.	259	261	AGT	848	850	AGT	263;263;266	A,T,C;G;T	261,1,1;263;266	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	1	SNP	p	S87I	0	.	.	259	261	AGT	848	850	AGT	263;263;266	A,T,C;G;T	261,1,1;263;266	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	1	SNP	p	S87W	0	.	.	259	261	AGT	848	850	AGT	263;263;266	A,T,C;G;T	261,1,1;263;266	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5946	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3425	216.4	1	SNP	p	S88P	0	.	.	262	264	TCC	851	853	TCC	267;269;271	T,G;C,T;C	266,1;268,1;271	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5394	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3244	207.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1869	1871	GGC	274;270;272	G;G,T;C	274;269,1;272	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1499	1501	GCA	329;328;327	G,T,A;C;A	327,1,1;328;327	penA.1.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1502	1504	ATC	327;326;325	A,G,C;T,A;C,A	325,1,1;325,1;324,1	penA.1.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1514	1516	GTG	320;322;319	G,C;T;G,T	319,1;322;318,1	penA.1.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1514	1516	GTG	320;322;319	G,C;T;G,T	319,1;322;318,1	penA.1.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2018	2020	ACC	310;311;308	A;C;C	310;311;308	penA.1.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2072	2074	GCG	272;268;270	G,A;C,A;G,C	271,1;267,1;269,1	penA.1.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2072	2074	GCG	272;268;270	G,A;C,A;G,C	271,1;267,1;269,1	penA.1.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2195	2197	GGC	315;314;314	G;G,T,A;C,T	315;312,1,1;313,1	penA.1.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2204	2206	GGC	314;309;309	G,T;G;C,A,T,G	313,1;309;305,2,1,1	penA.1.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	5236	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2807	232.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2222	2224	CCG	304;305;298	C,G,T,A;C;G	298,4,1,1;305;298	penA.1.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7146	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3582	248.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2862	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2171	163.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	787	787	C	249	C,A	248,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	T18M	NONSYN	52	54	ACG	504	506	ATG	315;313;312	A;T,G;G,T	315;312,1;311,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	879	881	CAA	305;308;310	C;A;A	305;308;310	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1086	1088	GAT	289;289;286	G,T,A;A;T,G	287,1,1;289;285,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1089	1091	GAT	285;282;282	G,T;A;T	284,1;282;282	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	V215T	NONSYN	643	645	GTT	1095	1097	ACT	283;282;283	A,G;C;T	282,1;281;282	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	R257M	NONSYN	769	771	AGG	1221	1223	ATG	387;385;383	A;T;G,T	387;385;382,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	R258S	NONSYN	772	774	AGG	1224	1226	AGC	381;377;375	A,G;G;C	380,1;377;375	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	A259G	NONSYN	775	777	GCT	1227	1229	GGT	373;370;364	G,T;G,T;T	372,1;369,1;364	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1341	1343	AAC	279;281;280	A;A;C	279;281;280	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	0	.	p	.	0	D333G	NONSYN	997	999	GAC	1449	1451	GGC	310;311;311	G,T;G,T;C	309,1;310,1;311	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3704	porB1b	1047	1047	98.57	porB1b.l6.c30.ctg.1	1919	239.7	1	SNP	p	G120K	0	.	.	358	360	GGC	810	812	GGC	285;288;290	G;G;C,G,A	285;288;288,1,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	13206	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5340	308.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2251	2253	CAT	335;334;337	C,A;A;T	334,1;334;337	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1840	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1425	161.0	1	SNP	p	V57M	0	.	.	169	171	GTG	741	743	GTG	306;306;310	G,C;T;G	305,1;306;310	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
